Lysteda TV ads make some networks squeamish

Share this article:
Lysteda TV ads make some networks squeamish
Lysteda TV ads make some networks squeamish
Ferring Pharmaceuticals is launching its first branded TV ad with spots for its Lysteda treatment for heavy menstrual bleeding.

The ad's up-front discussion of the condition, featuring the tagline “Help for heavy periods,” put network execs off,  with some initially refusing to air it. The spot depicts women walking serenely through falling rose petals to visualize the product's benefits.

“Periods are a natural part of a woman's life,” says the voiceover. “But what if your periods are unusually heavy? That may be a medical condition called heavy monthly bleeding.” Up to 22 million American women suffer from heavy monthly bleeding, according to Ferring.

The ad casts Lysteda as an alternative to hormones or surgery, “the first and only pill to help reduce heavy monthly bleeding by about one third.” It's part of an integrated campaign including print and branded and unbranded online elements.

The ads were spearheaded by Ferring VP US marketing Bill Garbarini and product manager Cicek Tilley. Creative concepts for the spots were developed by Integrated Media Solutions and DePirro/Garrone. The campaign is being executed by Integrated Communications Corp., Westfield Group Medical Communications and Kovak-Likely Communications.

Lysteda (tranexamic acid) won FDA approval as the first non-hormonal product for treatment of heavy menstrual bleeding in November, 2009, and Ferring acquired the drug from Xanodyne Pharmaceuticals in May.
 
Share this article:

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZenca beefs up respiratory portfolio

AstraZenca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.